---
layout: default
title: Ceritinib
parent: 僅模型預測 (L5)
nav_order: 95
evidence_level: L5
indication_count: 10
---

# Ceritinib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ceritinib: From ALK-Positive NSCLC to Fibromatosis, Gingival

## One-Sentence Summary

> Ceritinib is a second-generation ALK tyrosine kinase inhibitor whose established use — based on the literature in this evidence pack — is ALK-positive non-small-cell lung cancer (NSCLC).
> The TxGNN model's top-ranked prediction is **Fibromatosis, Gingival**, with a raw score of **99.86%**,
> but this is currently supported by **0 clinical trials** and **0 publications** — the model's own rationale flags it as likely embedding-space noise rather than a genuine mechanistic signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in Germany regulatory data (drug not marketed, 0 licenses); per literature evidence in this pack, ceritinib was developed for ALK-positive non-small cell lung cancer (NSCLC) |
| Predicted New Indication | Fibromatosis, Gingival |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 (model prediction only, no clinical trial or literature support) |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for ceritinib is not available (flagged as a High-severity data gap in this evidence pack). Based on the literature evidence attached to lower-ranked predictions in this pack, ceritinib is known to be an oral, potent ALK (anaplastic lymphoma kinase) inhibitor, and its efficacy in ALK-rearranged NSCLC has been established by Phase 3 randomised evidence (e.g., ASCEND-4). Mechanistically, ALK inhibitors would be expected to have therapeutic relevance only in diseases with a demonstrated ALK-driven pathology (e.g., ALK+ NSCLC, ALK-mutated neuroblastoma, anaplastic large cell lymphoma).

For the top-ranked candidate in this pack, **Fibromatosis, Gingival**, no such ALK-driven pathology has been reported in the literature. The evidence pack's own repurposing rationale states this explicitly: *"牙齦纖維瘤病無已知 ALK 通路涉入之報導，TxGNN 高分推測為 embedding 空間鄰近雜訊，無機轉支持"* (gingival fibromatosis has no known ALK pathway involvement; the high TxGNN score is likely attributable to embedding-space proximity noise, not mechanistic support). This is corroborated by the complete absence of clinical trial and literature evidence (0/0) for this specific indication.

It is worth noting that within the same evidence pack, other lower-ranked predictions (e.g., rank 5 "lung benign neoplasm," rank 7 "lung germ cell tumor") carry substantially richer literature bodies — though these too show disease-label/evidence mismatches, since the attached studies concern ALK+ malignant NSCLC and ALK-driven neuroblastoma rather than the benign/germ-cell entities nominally predicted. None of the top-10 predictions in this pack currently have evidence that directly and specifically supports the labeled indication.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Germany Market Information

Ceritinib is currently **not marketed in Germany** (market status: 未上市) with **0 registered authorizations**. No license records are available to extract product name, dosage form, or approved indication text.

---

## Cytotoxicity

Ceritinib is an antineoplastic agent (ALK tyrosine kinase inhibitor; per literature in this pack, developed for and studied in ALK-positive NSCLC).

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (ALK tyrosine kinase inhibitor) — not a conventional cytotoxic agent |
| Myelosuppression Risk | Not specified in this evidence pack; as a targeted small-molecule TKI, myelosuppression is generally expected to be lower than with conventional cytotoxic chemotherapy — please refer to the package insert |
| Emetogenicity Classification | Low to moderate — GI toxicity (nausea, vomiting, diarrhea) is a recognised class effect referenced in the literature (e.g., ASCEND-8 food-effect subgroup analysis) |
| Monitoring Items | Liver function tests (hepatotoxicity), QT interval/ECG (QT prolongation reported as a class effect for ALK TKIs including ceritinib), blood glucose, CBC |
| Handling Protection | Oral targeted therapy — hazardous drug handling precautions per institutional oncology pharmacy protocol are still advised, though generally less stringent than IV cytotoxic chemotherapy handling requirements |

---

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all marked as data gaps in this evidence pack; TFDA/BfArM package insert data is flagged as a **Blocking**-severity gap that prevents entry into S1 safety pre-assessment.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (Fibromatosis, Gingival) has zero supporting clinical trials or literature, and the evidence pack's own mechanistic rationale identifies the high TxGNN score as likely computational noise rather than a genuine biological signal. Combined with the Blocking-severity data gap on safety/warnings, this candidate cannot proceed past S0.

**To proceed, the following is needed:**
- TFDA/BfArM package insert data (warnings, contraindications) — currently a Blocking data gap
- DrugBank-sourced mechanism of action (MOA) data — currently a High-severity gap
- If repurposing exploration continues for this drug, prioritize re-scoring or manual curation of lower-ranked candidates with richer but currently mismatched evidence (e.g., rank 7 "lung germ cell tumor," where literature actually concerns ALK-driven neuroblastoma and a completed CNS-penetration trial) rather than the rank-1 candidate presented here
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

